JP2023517035A - 間葉系統前駆または幹細胞を使用して炎症性肺疾患を治療するための方法 - Google Patents

間葉系統前駆または幹細胞を使用して炎症性肺疾患を治療するための方法 Download PDF

Info

Publication number
JP2023517035A
JP2023517035A JP2022553155A JP2022553155A JP2023517035A JP 2023517035 A JP2023517035 A JP 2023517035A JP 2022553155 A JP2022553155 A JP 2022553155A JP 2022553155 A JP2022553155 A JP 2022553155A JP 2023517035 A JP2023517035 A JP 2023517035A
Authority
JP
Japan
Prior art keywords
cells
subject
stem cells
mlpscs
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022553155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517035A5 (cg-RX-API-DMAC7.html
Inventor
シルヴィウ・イテスク
Original Assignee
メゾブラスト・インターナショナル・エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900685A external-priority patent/AU2020900685A0/en
Application filed by メゾブラスト・インターナショナル・エスアーエールエル filed Critical メゾブラスト・インターナショナル・エスアーエールエル
Publication of JP2023517035A publication Critical patent/JP2023517035A/ja
Publication of JP2023517035A5 publication Critical patent/JP2023517035A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022553155A 2020-03-05 2021-03-04 間葉系統前駆または幹細胞を使用して炎症性肺疾患を治療するための方法 Pending JP2023517035A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020900685 2020-03-05
AU2020900685A AU2020900685A0 (en) 2020-03-05 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
PCT/EP2021/055483 WO2021176001A1 (en) 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Publications (2)

Publication Number Publication Date
JP2023517035A true JP2023517035A (ja) 2023-04-21
JP2023517035A5 JP2023517035A5 (cg-RX-API-DMAC7.html) 2024-03-13

Family

ID=74867509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022553155A Pending JP2023517035A (ja) 2020-03-05 2021-03-04 間葉系統前駆または幹細胞を使用して炎症性肺疾患を治療するための方法

Country Status (9)

Country Link
US (1) US12697355B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114418B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023517035A (cg-RX-API-DMAC7.html)
KR (1) KR20220150919A (cg-RX-API-DMAC7.html)
CN (1) CN115361958A (cg-RX-API-DMAC7.html)
AU (1) AU2021232614A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017557A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170255A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021176001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087933A1 (en) * 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
WO2018151046A1 (ja) * 2017-02-15 2018-08-23 ロート製薬株式会社 肺線維症治療剤、ptprr発現促進剤及び肺線維症治療用キット
WO2019051623A1 (es) * 2017-09-16 2019-03-21 Cells For Cells S.A. Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO1999003973A1 (en) 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
WO1999047163A2 (en) 1998-03-18 1999-09-23 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
WO1999051247A1 (en) 1998-04-03 1999-10-14 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
JP2002510655A (ja) 1998-04-03 2002-04-09 オシリス セラピューティクス,インコーポレイテッド 免疫抑制剤としての間葉幹細胞によるt細胞応答を阻害する方法とその利用
US6030836A (en) 1998-06-08 2000-02-29 Osiris Therapeutics, Inc. Vitro maintenance of hematopoietic stem cells
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU7611500A (en) 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
WO2004009767A2 (en) 2002-07-23 2004-01-29 Boston Scientific Limited Cell therapy for regeneration
US20060210544A1 (en) 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
ES2385450T3 (es) 2004-03-22 2012-07-25 Osiris Therapeutics, Inc. Células madre mesenquimatosas y sus utilizaciones
JP5162756B2 (ja) 2005-04-14 2013-03-13 財団法人ヒューマンサイエンス振興財団 医薬組成物及びその製造方法
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
CN101370930A (zh) 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
EP2057195A4 (en) 2006-08-29 2010-05-12 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE SUPPRESSION OF APOPTOSIS AND METHOD OF ADMINISTERING THE SAME
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
EP2578677A1 (en) 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
KR101039235B1 (ko) 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
KR101995016B1 (ko) 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
MX2011001730A (es) 2008-08-14 2011-03-24 Osiris Therapeutics Inc Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
KR101871472B1 (ko) 2010-07-02 2018-06-27 메소블라스트, 아이엔씨. 이식편대숙주 질환의 치료 방법
CA2809272A1 (en) 2010-08-31 2012-03-08 Cook General Biotechnology Llc Systemic, allogenic stem cell therapies for treatment of diseases in animals
EP2714057B1 (en) 2011-06-03 2019-11-06 Mesoblast, Inc. Methods of treating or preventing neurological diseases
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
JP6173157B2 (ja) 2013-10-02 2017-08-02 日本製薬株式会社 Il−17産生抑制組成物
WO2015061839A1 (en) 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
KR102577698B1 (ko) 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
WO2016086020A1 (en) 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
CN107206027A (zh) 2014-12-23 2017-09-26 迈索布拉斯特国际有限公司 进行性心力衰竭的预防
CN105796598A (zh) 2014-12-29 2016-07-27 西比曼生物科技(上海)有限公司 一种用于治疗慢性阻塞性肺疾病的脂肪间充质祖细胞复合物
US20180037867A1 (en) 2015-03-04 2018-02-08 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
AU2016258980B2 (en) 2015-05-05 2022-02-17 Mesoblast International Sàrl Potency assay
EP3619294A1 (en) 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
EP4772245A3 (en) 2019-01-02 2026-08-19 Mesoblast International Sàrl Method for treating lower back pain
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
US20220160776A1 (en) 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
CN113853206A (zh) 2019-05-23 2021-12-28 迈索布拉斯特国际有限公司 脑梗塞的功能恢复
EP3994245A1 (en) 2019-07-05 2022-05-11 Case Western Reserve University Priming media and methods for stem cell culture and therapy
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
KR20220143092A (ko) 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
CN111297899A (zh) * 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN115297875A (zh) 2020-03-11 2022-11-04 迈索布拉斯特国际有限公司 治疗炎症性肠病的方法ii
BR112022017560A2 (pt) 2020-03-11 2022-12-27 Mesoblast Int Sarl Método para tratar doença inflamatória intestinal i
JP2023520233A (ja) 2020-04-03 2023-05-16 メゾブラスト・インターナショナル・エスアーエールエル 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法
JP2023524660A (ja) 2020-04-28 2023-06-13 ファクター バイオサイエンス インコーポレイテッド 間葉系幹細胞療法
CA3181611A1 (en) 2020-06-11 2021-12-16 Paul Simmons 3d culture of mesenchymal lineage precursor or stem cells
US20230398154A1 (en) 2020-08-10 2023-12-14 Mesoblast International Sárl A composition comprising mesenchymal precursor or stem cells and their use
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
WO2022132986A2 (en) 2020-12-15 2022-06-23 Mesoblast International Sarl Method of treating progressive heart failure in subjects with class ii heart failure
CN112522191B (zh) 2020-12-18 2023-05-12 云南中科灵长类生物医学重点实验室 一种间充质干细胞的培养方法
AU2022210364A1 (en) 2021-01-22 2023-08-31 Mesoblast International Sàrl Opioid sparing compositions and methods of using the same
BR112023021840A2 (pt) 2021-04-23 2024-02-06 Mesoblast Int Sarl Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
AU2022394471A1 (en) 2021-11-17 2024-06-20 Mesoblast International Sarl Method of treating progressive heart failure in subjects at high risk of poor outcomes
US20250032552A1 (en) 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3257272A1 (en) 2022-05-26 2023-11-30 Mesoblast International Sàrl HIGH FLOW FILTER AND METHOD OF USE
EP4536253A1 (en) 2022-06-08 2025-04-16 Mesoblast International Sàrl Mesenchymal progenitor cells for enhancing partial reprogramming of target cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087933A1 (en) * 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
WO2018151046A1 (ja) * 2017-02-15 2018-08-23 ロート製薬株式会社 肺線維症治療剤、ptprr発現促進剤及び肺線維症治療用キット
WO2019051623A1 (es) * 2017-09-16 2019-03-21 Cells For Cells S.A. Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BMC PUBLIC HEALTH, vol. Vol.20, Article number:6, JPN6024051413, January 2020 (2020-01-01), ISSN: 0005630920 *
CHEST, vol. 143, no. 6, JPN6024051409, 2013, pages 1590 - 1598, ISSN: 0005630918 *
ENGINEERING, vol. 6, JPN6024051411, February 2020 (2020-02-01), pages 1153 - 1161, ISSN: 0005833910 *
JOURNAL OF BIOMEDICAL SCIENCE, vol. Vol.23, Article number:76, JPN6024051412, 2016, ISSN: 0005630921 *
RESPIRATORY RESEARCH, vol. Vol.15, Article number:39, JPN6024051410, 2014, ISSN: 0005630922 *
STEM CELL RESEARCH & THERAPY, vol. 11, no. 60, JPN6025026160, 13 February 2020 (2020-02-13), pages 1 - 14, ISSN: 0005630917 *
日本職業・災害医学会会誌, vol. 62, no. 3, JPN6024051414, 2014, pages 184 - 188, ISSN: 0005630919 *

Also Published As

Publication number Publication date
AU2021232614A1 (en) 2022-09-29
BR112022017557A2 (pt) 2022-12-27
EP4114418A1 (en) 2023-01-11
CN115361958A (zh) 2022-11-18
EP4114418B1 (en) 2026-05-20
CA3170255A1 (en) 2021-09-10
US20230293589A1 (en) 2023-09-21
WO2021176001A1 (en) 2021-09-10
US12697355B2 (en) 2026-08-04
KR20220150919A (ko) 2022-11-11

Similar Documents

Publication Publication Date Title
TWI698242B (zh) 利用血管母細胞產生間葉基質細胞之方法
US20090274665A1 (en) Stem Cells For Treating Lung Diseases
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
US20230165904A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
JP2023513847A (ja) 慢性移植片対宿主病の治療方法
JP2023517641A (ja) 炎症性腸疾患を治療するための方法ii
US20240197787A1 (en) Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
JP2023517636A (ja) 炎症性腸疾患を治療するための方法i
WO2023119239A1 (en) Method of treating severe graft versus host disease
KR20230119676A (ko) 클래스 ii 심부전 환자의 진행성 심부전 치료 방법
WO2007019107A2 (en) Adipose tissue stem cells, perivascular cells and pericytes
CN117337184A (zh) 使用间充质谱系前体细胞或干细胞治疗急性呼吸窘迫综合征(ards)的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260807